PWMS News Search Results

Back to NewsWire Home
Back to
  Back to PeopleWithMS NewsWire 

September 2008 Off the Wire . . .



News Article 02raw

Regulatory Immune Cells Not Defective In Multiple Sclerosis

Article Provided by: Pub Med
Article Date: 05 Sep 2008

Department of Neuroscience, Neurologic Clinics, Tor Vergata University, Rome, Italy; European Center for Brain Research (CERC)/Fondazione Santa Lucia, Rome, Italy

Background: Natalizumab is prescribed in Italy in patients who experienced at least two clinical relapses during a 12-month therapy with other approved immunomodulatory agents.Results: In 7 of 35 patients selected on the basis of these recommendations, we have observed clinical relapses occurring within 24 h after the first dose of natalizumab.Conclusion: The mechanism by which a first injection of natalizumab may precipitate a clinical relapse in patients with MS is unknown. We speculate that natalizumab can promote the release of inflammatory mediators from lymphocytes present in the central nervous system at the time of the first infusion, thus favoring the clinical manifestation of a pre-existing active lesion.

PMID: 18701574 [PubMed - in process]

E-Mail the NewsWire e-mail the NewsWire ! ! ! - Handpainted and Customized Canes
 with any news items you discover 

copyright 2003